Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2558MR)

This product GTTS-WQ2558MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Ewing sarcoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2558MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1569MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ3795MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ2984MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ12474MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ3114MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ11888MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ15279MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ5374MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW